US Patent 12,268,745: Scope, Claims, and U.S. Patent Landscape (Renal Pelvis Cancer With Mitomycin C in Thermoreversible Hydrogel)
What is the core claim scope of US 12,268,745?
US 12,268,745 is a method patent for treating renal pelvis cancer by administering mitomycin C delivered in a thermoreversible hydrogel whose composition is constrained by four quantitative material ranges. The claims are directed to: (1) preparing a mitomycin C-containing composition in a specific thermoreversible hydrogel matrix, and (2) administering it to a human renal pelvis cancer site.
Claim 1: Overall independent claim structure
Claim 1 requires all of the following elements:
A. Therapeutic intent and patient site
- Treat renal pelvis cancer.
- Administer to the renal pelvis of a human in need of treatment.
B. Drug and excipient combination
- Prepare a composition by incorporating:
- An effective amount of mitomycin C
- An accompanying excipient that is mannitol
C. Delivery vehicle: thermoreversible hydrogel with defined formulation
The thermoreversible hydrogel must comprise four components with specified weight ranges (w/w):
- (i) 23% to 27% poloxamer 407
- (ii) 0.15% to 0.2% hydroxypropylmethylcellulose
- (iii) 0.5% to 1.8% PEG-400
- (iv) water
D. Administration step
- Administer the composition to the renal pelvis.
Narrowing dependent claims: administration route and sub-ranges
Claims 2 to 8 narrow Claim 1 in two ways: catheter route and specific end-point formulation ranges.
Claim 2
- Administration via a urinary catheter.
Claim 3
- Thermoreversible hydrogel comprises 27% (w/w) poloxamer 407.
Claim 4
- Thermoreversible hydrogel comprises 0.2% (w/w) hydroxypropylmethylcellulose.
Claims 5, 7, 8 (PEG-400 sub-ranges)
- Claim 5: PEG-400 0.5% to 1.0% (w/w)
- Claim 7: PEG-400 0.5% to 1.0% (w/w) (depends from claim 6)
- Claim 8: PEG-400 1.0% (w/w) (single-point endpoint)
Claim 6
- Depends from claim 2 and sets:
- hydroxypropylmethylcellulose = 0.2% (w/w)
What the claim math implies for infringement
For Claim 1, all composition constraints must be met simultaneously. This creates a “formulation box” defined by the combination of:
- poloxamer 407: 23–27%
- HPMC: 0.15–0.2%
- PEG-400: 0.5–1.8%
- water: remainder
- plus mannitol as the accompanying excipient
- plus mitomycin C as active
The dependent claims further lock the route (urinary catheter) and tighten endpoints (poloxamer 27%, HPMC 0.2%, PEG-400 to 0.5–1.0% or exactly 1.0%).
How broad or narrow is the protection in formulation and use?
The patent’s practical scope is governed by two dimensions:
-
Use/indication specificity
- Renal pelvis cancer is the defined disease context.
- This limits direct coverage to use cases within that indication (in the context of the method claim).
-
Vehicle formulation specificity
- The hydrogel is not “any thermoreversible hydrogel.” It is constrained by narrow numeric ranges for three excipient/gelation-related ingredients.
Independent claim breadth assessment (Claim 1)
- Broader than a single formula because it covers ranges for poloxamer 407, HPMC, and PEG-400.
- Narrower than a general class because numeric constraints are strict and combined with:
- mitomycin C
- mannitol as the accompanying excipient
- thermoreversible hydrogel requirement
- delivery to the renal pelvis
Dependent claim impact
Dependent claims enforce specific points:
- poloxamer 407 at 27% (Claim 3)
- HPMC at 0.2% (Claims 4 and 6)
- PEG-400 at 1.0% (Claim 8)
- route via urinary catheter (Claim 2)
This structure gives the patent layered coverage: a broad core (Claim 1) with multiple narrower claim fallbacks.
What is covered versus what is likely outside claim scope?
Within scope (elements that must be present)
A method likely falls within at least Claim 1 if it includes:
| Element |
Requirement from Claim 1 |
| Disease and target |
Treat renal pelvis cancer; administer to renal pelvis of a human |
| Active drug |
Mitomycin C at an effective amount |
| Accompanying excipient |
Mannitol |
| Thermoreversible hydrogel composition |
Poloxamer 407 23–27% (w/w); HPMC 0.15–0.2% (w/w); PEG-400 0.5–1.8% (w/w); water |
| Method framing |
Prepare composition by incorporating drug/excipient into thermoreversible hydrogel and administer |
Likely outside scope (typical design-around pressure points)
Because the claim is conjunctive, variants can fall outside if they deviate on any one required component or numeric range. The most direct pressure points are:
- Mannitol inclusion
- The claim requires the accompanying excipient to be mannitol.
- Thermoreversible hydrogel formulation ranges
- Poloxamer 407 outside 23–27%
- HPMC outside 0.15–0.2%
- PEG-400 outside 0.5–1.8%
- Route limitation in dependent claims
- Urinary catheter route is only explicitly required in Claims 2 and its downstream dependent claims; for Claim 1 it is not required.
What does the claim set indicate about the invention’s likely technical focus?
The independent claim’s constraints point to a formulation-engineering approach where:
- Poloxamer 407 controls thermoreversible gel behavior in a defined loading band (23–27% w/w).
- HPMC and PEG-400 act as viscosity/modulation components within tight bands.
- Mannitol functions as the required accompanying excipient.
- Mitomycin C is delivered locally to the renal pelvis via a gel state that can be applied and then presumably gel/retains locally (inferred from “thermoreversible hydrogel” language).
This is not a broad drug-salt or dosing regimen claim. It is a delivery system composition plus use claim.
What is the U.S. patent landscape likely to look like for this space?
Without performing a live query of prosecution histories, continuations, and citing documents, the landscape can only be characterized at the structural level provided by the claim text you supplied. The credible landscape elements typically cluster into these buckets:
-
Prior art and follow-on patents for mitomycin C local delivery
- Systemic chemotherapy is well known across uro-oncology.
- Local renal collecting system delivery is also a known direction in bladder/upper tract oncology.
-
Thermoreversible hydrogel platforms using poloxamer-based formulations
- Poloxamer 407 thermoreversible gel systems are a mature formulation approach.
- Hydrogel tailoring by adding PEG and cellulose derivatives is common across drug delivery patents.
-
Route-specific implementations
- Urinary catheter administration is a common enabling delivery mechanism in uro-oncology local therapy patents.
-
Upper tract-specific device and method patents
- Renal pelvis cancer is narrower than “upper urinary tract” in general.
- Method claims that explicitly tie to renal pelvis cancer are usually less common than broad “urothelial carcinoma” scope, but they can exist as formulation-use claims.
How to interpret “landscape risk” for competitors
For a competitor seeking to invalidate or avoid infringement, the highest-risk overlap generally sits at the intersection of:
- mitomycin C
- renal pelvis cancer (or explicit renal collecting system targeting)
- thermoreversible gel made with poloxamer 407
- PEG-400 and HPMC with similar loadings
- mannitol as the required accompanying excipient
- urinary catheter delivery (if matching dependent claims)
A formulation that is thermoreversible and poloxamer-based but changes one required axis (like mannitol, or HPMC band, or PEG band) can fall outside literal scope. A different active (not mitomycin C) or a different site (not renal pelvis) removes coverage.
What is the likely claim interpretation strategy in U.S. litigation?
Core issues likely to be litigated
- Literal infringement by formulation
- Whether the alleged product/hydrogel matches each numeric range and the required excipient identity (mannitol).
- Route of administration
- For Claims 2 and downstream dependent claims: whether administration is via urinary catheter.
- Thermoreversible hydrogel characterization
- Whether the accused composition qualifies as a thermoreversible hydrogel within the claim language.
Most favorable claim “anchors” for the patentee
- The claim’s explicit numeric ranges for three components.
- The explicit excipient identity: mannitol.
- The explicit indication and anatomical target: renal pelvis cancer and renal pelvis.
- The explicit route: urinary catheter (in Claim 2).
Most favorable design-around pressure points
- Use a different excipient package instead of mannitol.
- Move outside at least one required numeric band for poloxamer 407, HPMC, or PEG-400.
- Change administration route if targeting the dependent claims (catheter).
- Use a different gel system that avoids the required formulation constraints even if thermoreversible.
Claim chart: mapping your supplied claim set
Claim 1 (independent)
- Treat renal pelvis cancer
- Prepare composition with:
- mitomycin C (effective amount)
- mannitol (accompanying excipient)
- thermoreversible hydrogel with:
- poloxamer 407: 23–27% w/w
- hydroxypropylmethylcellulose: 0.15–0.2% w/w
- PEG-400: 0.5–1.8% w/w
- water
- Administer to renal pelvis of a human
Claim 2 (dependent)
- Claim 1 plus urinary catheter administration
Claim 3 (dependent)
- Claim 2 plus poloxamer 407 = 27% w/w
Claim 4 (dependent)
- Claim 2 plus HPMC = 0.2% w/w
Claim 5 (dependent)
- Claim 2 plus PEG-400 = 0.5–1.0% w/w
Claim 6 (dependent)
- Claim 2 plus HPMC = 0.2% w/w
Claim 7 (dependent)
- Claim 6 plus PEG-400 = 0.5–1.0% w/w
Claim 8 (dependent)
- Claim 7 plus PEG-400 = 1.0% w/w
Key Takeaways
- US 12,268,745 is a formulation-and-method patent: it claims treating renal pelvis cancer with mitomycin C in a thermoreversible hydrogel that has a tight, combined numeric formulation box.
- Claim 1 coverage is driven by three numeric bands: poloxamer 407 (23–27% w/w), HPMC (0.15–0.2% w/w), PEG-400 (0.5–1.8% w/w), plus mandatory excipient identity mannitol.
- Dependent claims add layered narrowing: urinary catheter delivery (Claim 2) and specific end-point components (poloxamer 27%, HPMC 0.2%, PEG-400 0.5–1.0%, and PEG-400 exactly 1.0%).
- Landscape risk for competitors is highest where their product matches all axes simultaneously: active (mitomycin C), indication/anatomy (renal pelvis cancer; renal pelvis), gel platform (thermoreversible hydrogel with poloxamer 407), excipient (mannitol), and the specific loading bands for HPMC and PEG-400.
FAQs
1) Does the patent require urinary catheter delivery?
No for Claim 1. Urinary catheter appears in Claim 2 and thus in Claims 3–8.
2) Are the excipient identities fully specified in Claim 1?
Yes for the “accompanying excipient” (mannitol) and for gel components (poloxamer 407, HPMC, PEG-400, and water).
3) What single formulation change is most likely to avoid Claim 1 literal coverage?
Changing any required component out of its specified w/w range, or omitting/replacing mannitol.
4) Which claims include the tight PEG-400 endpoint at 1.0%?
Claim 8 (PEG-400 = 1.0% w/w), which depends from Claim 7 (PEG-400 0.5–1.0% w/w) and earlier claims.
5) Is the protection limited to renal pelvis cancer rather than upper tract urothelial cancers broadly?
Yes. Claim 1 specifies renal pelvis cancer.
References
[1] U.S. Patent 12,268,745 (claims provided in prompt text).
